Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .
Commentary by Neil M. Bressler, MD
JAMA. 2004;291(15):1900-1901.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
ARCHIVES OF OPHTHALMOLOGY
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group
Objective To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender.
Methods Summary prevalence estimates of drusen 125 µm or larger, neovascular AMD, and geographic atrophy were prepared separately for black and white persons in 5-year age intervals starting at 40 years. The estimated rates were based on a meta-analysis of recent population-based studies in the United States, Australia, and Europe. These rates were applied to 2000 US Census data and to projected US population figures for 2020 to estimate the number of the US population with drusen and AMD.
Results The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% . . . [Full Text of this Article]
Author Affiliations: Wilmer Eye Institute and Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Md.
RELATED ARTICLE
Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group
Arch Ophthalmol. 2004;122(4):564-572.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Dietary {omega}-3 Fatty Acid and Fish Intake in the Primary Prevention of Age-Related Macular Degeneration: A Systematic Review and Meta-analysis
Chong et al.
Arch Ophthalmol 2008;126:826-833.
ABSTRACT
| FULL TEXT
Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin
Izumi-Nagai et al.
IOVS 2008;49:1679-1685.
ABSTRACT
| FULL TEXT
Macular Pigment Lutein Is Antiinflammatory in Preventing Choroidal Neovascularization
Izumi-Nagai et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:2555-2562.
ABSTRACT
| FULL TEXT
Improved Vision-Related Function After Ranibizumab Treatment of Neovascular Age-Related Macular Degeneration: Results of a Randomized Clinical Trial
Chang et al.
Arch Ophthalmol 2007;125:1460-1469.
ABSTRACT
| FULL TEXT
Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis
Chong et al.
BMJ 2007;335:755-755.
ABSTRACT
| FULL TEXT
Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: Year 1 Results of the FOCUS Study.
Heier et al.
Arch Ophthalmol 2006;124:1532-1542.
ABSTRACT
| FULL TEXT
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld et al.
NEJM 2006;355:1419-1431.
ABSTRACT
| FULL TEXT
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown et al.
NEJM 2006;355:1432-1444.
ABSTRACT
| FULL TEXT
|
